Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-054819
Filing Date
2025-06-16
Accepted
2025-06-16 17:00:58
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 17912
2 JOINT FILING AGREEMENT ea024587101ex99-a_urogen.htm EX-99.A 13615
  Complete submission text file 0001213900-25-054819.txt   33194
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Subject) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89992 | Film No.: 251050936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

EIN.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G